OTLC.US Oncotelic Therapeutics Inc
- Market cap
- USD 4.58M
- P/E
- 0.0x
- P/B
- 0.02x
- ROE
- -1.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is OTLC.US undervalued?
Graham numberThe Graham number of Oncotelic Therapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oncotelic Therapeutics Inc fundamental analysis
No fundamental analysis for Oncotelic Therapeutics Inc yet.
Oncotelic Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oncotelic Therapeutics Inc
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications in the United States. The company develops antisense and small molecule injectable drugs for the treatment of cancer. It is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer, m…
Full company profileOncotelic Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oncotelic Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 341K | 1.74M | 0.00 | 0.00 | 70.0K | 0.00 | 0.00 | 500K |
| Operating Income | -13.8M | -3.00M | -4.31M | -7.58M | -9.13M | -5.61M | -565K | -376K | -3.19M | -5.39M |
| EBITDA | -13.8M | -3.00M | -5.83M | -7.61M | -8.45M | 7.66M | -7.16M | -3.92M | 361M | -2.57M |
| Net Income | -13.8M | -2.74M | -6.64M | -9.50M | -9.39M | 5.09M | -7.90M | -4.52M | 249M | -3.61M |
| EPS | -0.52 | -0.07 | -0.08 | -0.10 | -0.03 | 0.01 | -0.02 | -0.01 | 0.56 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 1.17M | 799K | 23.7M | 23.7M | 23.6M | 36.1M | 30.0M | 26.7M | 393M | 395M |
| Total Liabilities | 1.65M | 1.16M | 6.78M | 11.2M | 15.5M | 16.9M | 18.4M | 19.2M | 131M | 131M |
| Shareholders' Equity | -477K | -362K | 16.9M | 12.5M | 8.16M | 19.2M | 12.1M | 8.25M | 263M | 265M |
| Cash & Short-term Investments | 1.12M | 629K | 82.0K | 474K | 569K | 241K | 170K | 86.1K | 88.9K | 186K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.42M | -241K | -2.28M | -2.81M | -4.43M | -1.45M | -1.32M | -740K | -1.38M | -869K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -10.9M | -2.84M | -2.28M | -2.81M | -4.43M | -1.45M | -1.32M | -740K | -1.38M | -869K |
| Ratios | ||||||||||
| ROE | - | - | -39.3% | -76.1% | -115.1% | 26.5% | -65.2% | -54.8% | 94.9% | -1.4% |
| ROA | -1,178.5% | -342.6% | -28.0% | -40.2% | -39.8% | 14.1% | -26.3% | -17.0% | 63.4% | -0.9% |
| Net Profit Margin | - | - | -1,947.5% | -545.9% | - | - | -11,290.1% | - | - | -722.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Oncotelic Therapeutics Inc dividends
Oncotelic Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:12 on Dec 28, 2012.
Who owns Oncotelic Therapeutics Inc
- Insiders 43.82%
- Institutions 0.00%
- Public & others 56.18%
- Shares outstanding 458M
- Free float 235M
Oncotelic Therapeutics Inc company profile
- Company name
- Oncotelic Therapeutics Inc
- Ticker
- OTLC.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 38
- Fiscal year end
- December
- Address
- 29397 Agoura Road, Agoura Hills, CA, United States, 91301
- Phone
- 650 635 7000
- Website
- oncotelic.com
About Oncotelic Therapeutics Inc
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications in the United States. The company develops antisense and small molecule injectable drugs for the treatment of cancer. It is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer, melanoma, and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, the company develops CA4P for the treatment of advanced metastatic melanoma; AL-101, an intranasal drug and delivery system for intra-nasal apomorphine for the treatment of parkinson's disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies, as well as nanoparticle products for the treatment of various cancers. The company is based in Agoura Hills, California.
Oncotelic Therapeutics Inc management
7- Dr. Vuong Trieu Ph.D.CEO, President & Chairman · born 1963
- Mr. Amit ShahChief Financial Officer · born 1967
- Dr. Anthony E. Maida III, B.A., MA, MBA, Ph.D.Chief Medical Officer ? Translation Medicine & Director · born 1952
- Mr. Saranjit SaundCBO & GM of AI Division · born 1958
- Dr. Larn Hwang Ph.D.Chief Scientific Officer · born 1963
- Dr. Seymour Howard Fein M.D.Chief Regulatory Officer & Chief Medical Officer (Consultant) · born 1949
- Mr. Steven W. KingConsultant & Director · born 1964